415 A phase I study evaluating the safety profile and pharmacokinetics of CS-1008 (Tigatuzumab), humanized monoclonal antibody targeting death receptor 5 (DR5), in Japanese patients with advanced solid tumours

✍ Scribed by H. Nokihara; N. Yamamoto; Y. Yamada; H. Asahina; T. Shibata; Y. Seki; Y. Tamura; K. Honda; S. Misawa; T. Tamura

• Book ID: 119603098
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 47 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)72122-4